Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Jazz Pharmaceuticals's Revenue for the
three
months ended in Jun. 2026 was $1,208 Mil. Jazz Pharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2026 was $859 Mil.
Hence, Jazz Pharmaceuticals's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.41.
Jazz Pharmaceuticals (NAS:JAZZ) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Jazz Pharmaceuticals Receivables Turnover Related Terms
Jazz Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAZZ vs BBIO, ASND, EXEL: Receivables Turnover Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (JAZZ) has a Receivables Turnover of 1.41 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jazz Pharmaceuticals and its competitors. According to the industry distribution chart, Jazz Pharmaceuticals ranks #379 out of 842 companies in the Biotechnology industry, placing it in the top 45%.
Is Jazz Pharmaceuticals' Receivables Turnover too high?
Jazz Pharmaceuticals' current Receivables Turnover is 1.41. The Biotechnology industry median Receivables Turnover is 5.30. Jazz Pharmaceuticals' value of 1.41 is 73.4% below this industry median. Based on the distribution chart, Jazz Pharmaceuticals ranks #379 out of 842 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Receivables Turnover compare to BBIO and ASND?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #379 out of 842 companies for Receivables Turnover. This puts Jazz Pharmaceuticals in the upper half of its industry. The industry median Receivables Turnover is 5.30. Jazz Pharmaceuticals' value of 1.41 is 73.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jazz Pharmaceuticals's current Receivables Turnover of 1.41 is 73.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current Receivables Turnover is 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $152.38, compared to a current price of $256.65 — trading 68.4% above its estimated fair value. The current Receivables Turnover is 1.41 and 73.4% below the Biotechnology industry median of 5.30. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Receivables Turnover is 1.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of $256.65 is trading 68.4% above its estimated GF Value™ of $152.38.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for JAZZ:
Receivables Turnover: 1.41
GF Value™: $152.38 vs. price of $256.65 (68.4% above fair value)
Industry Position: 73.4% below the Biotechnology median (#379 of 842)
No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score
Get the complete analysis for JAZZ
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAZZ has been successfully added to your 
